ZODIAC trial presented at AHA

The ZODIAC (NCT05844566) trial aimed to compare a DSS aligned with the 2019 ESC/EAS guidelines in addition to routine care with routine care alone in patients with ACS. The study aimed to assess whether the availability of a DSS resulted in early initiation of combination lipid-lowering therapies or the intensification of existing lipid-lowering therapy regimes over a 24-week period after an ACS event. An estimated 1,584 participants consented to randomized clinical trial sites to collect their data, where clinical sites were randomized to either standard of care or access to the DSS.

The trial was sponsored by Imperial College London, funded by Sanofi and delivered by ICTU Global.